Our finding that almost a third of patients identified as having CKD by eGFRcreat did not have CKD confirmed by expert physicians has important implications because it is likely that future pragmatic trials will need to include steps to re-test and further risk stratify patients (e.g., with albuminuria and cystatin C testing) to confirm CKD before deploying interventions. Here, CST3 is linked to chronic kidney disease.